INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
Key Highlights
- ➤INmune Bio (INMB) signs Uniphar agreement supporting Ebstrocel international commercialization
- ➤Named-patient access initially targets selected European and MENA markets
- ➤Uniphar framework may expand to broader distribution as approvals and reimbursement are secured
- ➤Ebstrocel remains investigational and lacks FDA, MHRA, EMA, or other regulatory approval
Expert Statements
David Moss, Chief Executive Officer of INmune Bio
“This agreement marks an important step in moving Ebstrocel™ from clinical development toward commercialization and bringing Ebstrocel to patients internationally.”
David Moss, Chief Executive Officer of INmune Bio
“Uniphar provides access to established market-access, distribution and order-to-cash capabilities across multiple international markets without requiring INmune Bio to build those capabilities country by country.”
David Moss, Chief Executive Officer of INmune Bio
“We believe this provides a capital-efficient way to pursue named-patient opportunities in appropriate markets while building the physician relationships, treatment-center experience and commercial infrastructure needed to support broader international commercialization.”
Ruth Rostron, Head of Expanded Access at Uniphar
“We are pleased to partner with INmune Bio as it prepares Ebstrocel for international commercialization.”
Ruth Rostron, Head of Expanded Access at Uniphar
“Uniphar has built an integrated global platform to help innovative medicines navigate the complexities of international access, distribution and commercialization.”
Ruth Rostron, Head of Expanded Access at Uniphar
“We believe our infrastructure and experience are well suited to support INmune Bio’s strategy for Ebstrocel, beginning with named-patient access opportunities and expanding as the product progresses through its regulatory and commercial journey.”
Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization
BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). INmune Bio initially intends to use the framework to pursue named-patient access in selected European countries and in the Middle East and North Africa (MENA), subject to applicable law and country-specific statements of work. The relationship may subsequently expand across Europe and other territories by mutual agreement.
Get started
Create a free account to read the full story.